Introduction With every article of the Microbiome Times, one sees the therapeutic microbiome industry edging ever-closer to full commercialisation of their products. Understandably, much of the focus has been on the challenging process of demonstrating […]
A new paper published today in Nature Communications introduces VIRGO, the first comprehensive non-redundant gene catalog of the human vaginal microbiome. Powered by the largest integrated data set of vaginal metagenomes and metatranscriptomes to date, […]
SkinBioTherapeutics, a life science company focused on skin health, announces that its wholly owned subsidiary, AxisBiotix Limited, has signed a development agreement with Winclove Probiotics B.V., (“Winclove”), a specialist in the research, development and manufacture of […]
DuPont Nutrition & Biosciences (DuPont) today announced a collaboration with the MRM Health NV (MRM Health), a biopharmaceutical company, focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health […]
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota from the damaging effects of antibiotics, today announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluatingDAV132 in patients […]
Many different chronic diseases have been associated with distinct gut microbiome ‘signatures’, but what has proved challenging to date is the translation of the compositional and functional microbiome differences into novel diagnostics and therapeutics. Moving […]
Rebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy aimed at breaking the cycle of recurrent Clostridioides difficile (C. diff) infection, […]
TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multicentric clinical study carried out on 229 subjects and evaluating the efficacy of Hafnia alvei HA4597™ in the weight loss by regulation […]
MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Crédit Mutuel Innovation, and Biocodex. The funding will enable […]
The human microbiome is often described as an ‘ecosystem’, evoking a complex collection of organisms that are alive and dynamic. So when considering strategies for modulating the human microbiome to prevent or treat a disease, […]
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as […]